Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
07/27 CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
07/27 CELGENE CORPORATION (NASDAQ : CELG) reported earnings of $1.82 per share beating..
07/27 CELGENE : N.J. drug company Celgene to pay $280M to settle suit over cancer drug
07/27 CELGENE : AG Ferguson Recovers Nearly $750k in Medicaid Funds From Pharma Compan..
07/27 CELGENE : beats Street 2Q forecasts
07/27 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Results of Operations and Finan..
07/27 CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
07/27 CELGENE : Reports Second Quarter 2017 Operating and Financial Results
07/27 CELGENE : Whistleblower Settles False Claims Act Suit Against Pharmaceutical Gia..
07/27 CELGENE : agrees one of the largest settlements for false claims on record
More news
News from SeekingAlpha
07/27 CELGENE : Expect The Story To Continue
07/27 Celgene (CELG) Q2 2017 Results - Earnings Call Transcript
07/27 Celgene Q2 revenues up 19%; non-GAAP EPS up 26%; updates guidance
07/27 Celgene Corporation 2017 Q2 - Results - Earnings Call Slides
07/27 This Is Critical For Stocks Today
Financials ($)
Sales 2017 13 171 M
EBIT 2017 7 486 M
Net income 2017 4 769 M
Debt 2017 2 621 M
Yield 2017 -
P/E ratio 2017 24,14
P/E ratio 2018 19,55
EV / Sales 2017 8,37x
EV / Sales 2018 6,92x
Capitalization 107 559 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 143 $
Spread / Average Target 4,1%
EPS Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN17.74%129 349
ACTELION21.32%30 573